Liu Jing, Song Guang, Meng Tao, Ji Lu
a Department of Obstetrics , The First Affiliated Hospital of China Medical University , Shenyang , China.
b Department of Ultrasound , Shengjing Hospital of China Medical University , Shenyang , China.
J Matern Fetal Neonatal Med. 2019 Oct;32(19):3168-3175. doi: 10.1080/14767058.2018.1459551. Epub 2018 Apr 12.
It is unclear that whether Foley catheter with simultaneous oxytocin could improve the efficacy of induction outcome. To conduct a meta-analysis of randomized controlled trial (RCT) studies to evaluate the effect of Foley catheter with simultaneous oxytocin on labor induction. PubMed, Embase, and other databases were searched from their inception to July 2017. We included all RCTs comparing Foley catheter with simultaneous oxytocin (i.e. intervention group) with Foley catheter followed by oxytocin (i.e. control group) in the three kinds of women (nulliparas and multiparas/only nulliparas/only multiparas). We estimate summarized relative risk (RR) and 95% confidence intervals (CIs) for dichotomous outcomes, standard mean difference for continuous outcomes. Fixed- and random-effects models were used, depending on heterogeneity. After application of our inclusion and exclusion criteria, six RCTs with a total of 1133 participants were identified. We found that only nulliparas had significant RR of delivery within 24 h (RR = 1.32, 95% CI: 1.12, 1.55, = 46.5%). Meanwhile, there was no statistically significant difference between intervention and control groups in vaginal delivery in 24 h, cesarean delivery, time to delivery, and Apgar score at 5 min less than 7. Foley catheter with simultaneous oxytocin did not increase the risk of side effects, included chorioamnionitis, postpartum hemorrhage, uterine hyperstimulation, and neonatal intensive care unit admission. The results seem to support the use of oxytocin to a Foley catheter at the initiation of labor induction, as it might lead to increases the rate of delivery within 24 h in nulliparas.
尚不清楚在引产时使用福莱导尿管联合缩宫素是否能提高引产效果。本研究旨在对随机对照试验(RCT)进行荟萃分析,以评估福莱导尿管联合缩宫素用于引产的效果。检索了PubMed、Embase及其他数据库,检索时间从建库至2017年7月。纳入了所有比较福莱导尿管联合缩宫素(即干预组)与先使用福莱导尿管再使用缩宫素(即对照组)的RCT,研究对象为三类女性(初产妇和经产妇/仅初产妇/仅经产妇)。对于二分类结局,我们估计汇总相对风险(RR)及95%置信区间(CI);对于连续型结局,估计标准化均数差。根据异质性情况使用固定效应模型和随机效应模型。在应用纳入和排除标准后,共确定了6项RCT,涉及1133名参与者。我们发现,仅初产妇在24小时内分娩的RR有显著差异(RR = 1.32,95%CI:1.12,1.55,I² = 46.5%)。同时,干预组和对照组在24小时内阴道分娩、剖宫产、分娩时间及5分钟时Apgar评分低于7分方面无统计学显著差异。福莱导尿管联合缩宫素并未增加包括绒毛膜羊膜炎、产后出血、子宫过度刺激及新生儿重症监护病房收治等副作用的风险。结果似乎支持在引产开始时将缩宫素与福莱导尿管联合使用,因为这可能会提高初产妇在24小时内的分娩率。